Marker Therapeutics Stock Target Price
| MRKR Stock | USD 1.25 0.05 3.85% |
Marker Therapeutics fundamentals help investors to digest information that contributes to Marker Therapeutics' financial success or failures. It also enables traders to predict the movement of Marker Stock. The fundamental analysis module provides a way to measure Marker Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marker Therapeutics stock.
Marker | Target Price |
Marker Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marker Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics of similar companies.Marker Therapeutics is currently under evaluation in target price category among its peers.
Marker Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (1.80) % | ||||
| Operating Margin | (1.25) % | ||||
| Current Valuation | (4.52 M) | ||||
| Shares Outstanding | 10.71 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 41.80 % | ||||
| Number Of Shares Shorted | 149.81 K | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 2.58 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (5.6 M) | ||||
| EBITDA | (11.79 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 3.07 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 0.83 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Short Ratio | 1.80 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 10.33 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 13.92 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
| Net Asset | 17.13 M |
About Marker Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marker Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.